Yung Zip Chemical Ind. Co., Ltd. (4102) AI Stock Analysis

Yung Zip Chemical Ind. Co., Ltd.

(TPEx:4102)

Select Model

Rating:46Neutral

Price Target:TWD 17.50▲(0.00% Upside)

Action:initiatedcoverage

Date:11/09/26

Recent financial weakness from 2025 revenue and profit declines is the primary drag, alongside bearish technical momentum; high dividend yield provides limited valuation support.

Positive Factors

Moderate leverageModerate and declining leverage gives the company greater financial flexibility than in earlier years. Lower debt exposure can reduce balance-sheet pressure, preserve borrowing capacity, and provide a more durable foundation for navigating operating volatility or funding future investment.

Negative Factors

Revenue and margin contractionThe sharp decline in revenue and gross margin indicates materially weaker operating performance and reduced earnings resilience. If lower pricing, an unfavorable mix, or higher costs persist, the company may have less capacity to absorb industry pressure and restore prior profitability.

Yung Zip Chemical Ind. Co., Ltd. (4102) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 745.78M
Dividend Yield: 6.57%
Average Volume (3M): 24.27K
Price to Earnings (P/E): -905.6
Beta (1Y): 0.31
Revenue Growth: 7.67%
EPS Growth: 86.29%
Country: TW
Employees: 181
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - General

Yung Zip Chemical Ind. Co., Ltd. Business Overview & Revenue Model

Company Description

Yung Zip Chemical Ind. Co., Ltd. is a global provider specializing in the manufacture of essential pharmaceutical components. The company supplies active pharmaceutical ingredients (APIs), their intermediate precursors, and various specialty chemical...

Yung Zip Chemical Ind. Co., Ltd. Financial Statement Overview

Summary

Prior steady revenue and profit growth through 2024 was offset by sharp 2025 revenue drop, margin compression to 20%, and net loss, though balance sheet remains stable with low debt.

Income Statement

32Negative

Balance Sheet

70Positive

Cash Flow

37Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	494.04M	474.22M	583.70M	559.15M	567.33M	477.60M
Gross Profit	103.03M	94.57M	178.40M	173.89M	164.97M	104.51M
EBITDA	28.54M	17.00M	113.72M	106.58M	117.16M	49.84M
Net Income	1.13M	-14.36M	64.61M	62.51M	69.99M	6.00M
Balance Sheet
Total Assets	951.87M	924.11M	964.63M	990.27M	1.03B	930.25M
Cash, Cash Equivalents and Short-Term Investments	90.37M	95.04M	133.53M	124.11M	144.18M	78.20M
Total Debt	163.78M	157.41M	102.89M	152.29M	214.29M	252.59M
Total Liabilities	271.94M	256.81M	222.61M	282.49M	345.94M	353.87M
Stockholders Equity	599.16M	588.26M	664.37M	635.58M	613.57M	514.11M
Cash Flow
Free Cash Flow	-2.25M	-36.57M	80.17M	69.31M	66.40M	46.09M
Operating Cash Flow	20.18M	2.10M	118.67M	96.76M	92.55M	73.27M
Investing Cash Flow	-23.83M	-41.61M	-25.05M	-17.77M	16.80M	-35.34M
Financing Cash Flow	-11.67M	-439.00K	-86.44M	-97.36M	-44.34M	-13.13M

Yung Zip Chemical Ind. Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4102 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4102	46Neutral	TWD 741.54M	-905.61	―	6.57%	7.67%	86.29%
TW:4171	40Underperform	TWD 896.99M	-40.49	―	―	11.99%	84.94%

* General Sector Average

Performance Comparison

TW:4102 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4102	Yung Zip Chemical Ind. Co., Ltd.	17.50	-4.95	-22.05%
TW:4117	General Biologicals Corp.	7.41	-4.79	-39.26%
TW:4171	GeneReach Biotechnology Corp.	15.50	-4.55	-22.69%
TW:4724	Meribank Biotech Co Ltd	9.12	-7.83	-46.19%
TW:4732	Naturewise Biotech & Medicals Corporation	15.20	-4.90	-24.38%
TW:6493	TTBIO CORP.	28.80	-0.30	-1.03%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Yung Zip Chemical Ind. Co., Ltd. AI Stock Analysis